News

The asset was developed via ProBio’s biologics discovery and development operations and is directed against an oncology target. ProBio is set to receive an upfront payment, alongside eligibility

London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by

The company will advance zalsupindole into Phase II development and finance a broader pipeline expansion. The drug is being designed to treat psychiatric and psychological disorders. In animal

The deal includes potential payments reaching up to $75m depending on the business’ future financial performance. The units, located in Pennsylvania’s Exton, being sold generated around 40% of

Set to be marketed under the brand name Ashuli, the therapy represents the first Simponi (golimumab) biosimilar approved in the country. The regulatory clearance comes amid pronounced domestic

Under the agreement, the biotechnology company will work alongside researchers at Duke to conduct molecular profiling on tissue and blood samples gathered from the academic institution’s biobanks. The

Following completion of the merger, the combined entity will be named Brains Therapeutics and intends to list its common shares on the Nasdaq stock exchange under the BAPI

The additional indication approval covers radiographic and non-radiographic forms of the chronic inflammatory disease in individuals who show an inadequate response to conventional therapy. Alfasigma has also submitted

Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares. Hinova is eligible to receive the remainder of the deal